Table 2b.
Molecular Prognostic Effect Associated with SOX9
| Prognostic role | SOX9 expression | Sample size | Patients sample type | Effect | Refs |
|---|---|---|---|---|---|
| Poor | Up | >200 | Tissue | Associated with higher grade and ER negative tumor. Significantly shorter OS. Cytoplasmic accumulation associated with high proliferation for IDC and metastatic BC | [106] |
| Poor | Up | 306 | Tissue | Co-expression of Slug and Sox9 associated with poor overall survival | [19] |
| Poor | Up | 114 | Tissue | Associated with tumor subtype (high expression in TNBC) and histological grade | [46] |
| Poor | Up | 84 | Tissue (stroma) | Strong stromal expression after chemotherapy associated with shorter overall survival | [132] |
| Poor | Up | 420 | Tissue | High expression with high stem cell population associated with poor OS and DFS | [133] |
| Up in TNBC | 617 | Tissue | No significant association | [134] | |
| Poor | Up | 3951 | Tissue | Strong indicator of poor 5-years relapse free survival | [108] |
OS, overall survival; DFS, disease free survival; BC, breast cancer; IDC, invasive ductal carcinoma; TNBC, triple negative BC